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Edited by Sandro SonninoAbstract GD3-replica peptides were obtained from a phage
peptide library and an anti-GD3 monoclonal antibody (Mab)
(4F6), and anti-GD3 Mabs were generated by immunizing a pep-
tide GD3P4. AMab, 3D2 was found to recognize GD3 by immu-
nohistochemical approaches. Amino acid analysis of heavy and
light chain variable regions of 4F6 and 3D2 showed that the
respective chains had the same length, and only a few diﬀerent
amino acid substitutions were found. The present data indicate
that the immunogenic GD3P4 is processed in a certain size
and exposed on the antigen-presenting cells with a molecular
shape quite similar to that of the GD3 epitope in 4F6.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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presentation1. Introduction
Carbohydrates on tumor cell surfaces have been described as
tumor-associated antigens [1], and in particular, the presence of
disialogangliosides GD3 andGD2 has been well documented in
melanoma, small cell lung carcinoma, neuroblastoma, and gli-
oma [2–5], raising the possibility of immunotherapy using the
tumor-associated gangliosides as target antigens [6–8]. Some
monoclonal antibodies (Mabs) speciﬁc for these gangliosides
have been reported as anti-tumor drugs that led to suppression
of cell growth and induction of apoptosis of human tumor cells
[9–11].
When anti-idiotypic (Id) antibodies against anti-ganglioside
Mab are injected in animals, some anti-Id antibodies recog-
nize the original antigen gangliosides and such anti-Id anti-
bodies are good candidates for vaccine therapy [12–14].Abbreviations: Mab, monoclonal antibody; MAP, multi-antigen pep-
tide; VSSP, very small size protoliposomes; ITLC, immunostaining on
thin-layer chromatography plate; TMB, tetramethyl benzidine; CDR,
complementarity-determining regions; VH, heavy chain variable
region; VL, light chain variable region
*Corresponding author. Fax: +81 88 665 5662.
E-mail address: d_ishikawa@research.otsuka.co.jp (D. Ishikawa).
1 Authors equally contributed to this work.
0014-5793/$32.00  2006 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2006.01.063However, the whole anti-Id antibodies contain extra motifs,
except in the idiotope (antigen-mimicking domain) that may
account for the unexpected allergic reactions that are often
observed when anti-Id antibodies are administrated. This
problem could be overcome if the idiotopes are replaced by
oligopeptides.
We have tried to prepare peptides that mimic glyco-
sphingolipids using Mabs against glycosphingolipids using a
phage peptide library [15,16]. And the obtained peptides
showed function similar to the antigen glycosphingolipids,
such as inhibitory eﬀects on glycosidase [15], adhesion activity
of tumor cells to endothelial cells and tumor growth in in vivo
study [16]. In this study, we proposed to call glyco-replica pep-
tides to these peptides with similar functions with original
glycosphingolipids [16]. The possibility to produce peptides
that can mimic the carbohydrate structure in terms of molecu-
lar shape is one of great interests. If this working hypothesis is
correct, this phenomenon would explain a possible mechanism
of autoimmune disease such as Guillian Barre Syndrome and
other neuropathies. Another point is a production mechanism
of antibody against glycoconjugates via glyco-replica peptide
like process.
In these respects, in the present study, we have prepared
GD3-replica peptides using a phage peptide library and the
anti-GD3 Mab 4F6 [17]. The peptides thus obtained were
shown to induce antibodies recognizing GD3 following immu-
nization of mice with multi-antigen peptides (MAPs).2. Materials and methods
2.1. Materials
The pentadecamer random peptide library displayed on ﬁlamentous
phage (fd phage) surface protein (pIII) and the host bacterial strain
Escherihia coli K91Kan were provided by Dr. Y. Saya, Kumamoto
University, Kumamoto, Japan [18]. The phage library contains
approximately 1.5 · 108 individual peptides.
MAPs were synthesized from MAP resin (Watanabe Chemical
Co., Japan) using a peptide synthesizer ACT357 (Advanced
Chem.-Tech). Horseradish peroxidase (HRP)-conjugated antibodies
were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz,
CA). Mouse Monoclonal Antibody Isotyping Test Kit was pur-
chased from DAINIPPON Pharmaceutical Co. Ltd. (Osaka).
KOD plus was purchased from TOYOBO (Tokyo) and oligonucle-
otides mixture for cloning of mouse immunoglobulin heavy chain
was from Amersham Biosciences (Piscataway, NJ). The other oligo-
nucleotides were purchased from NIHON BIO SERVICE (Saitama,
Japan).blished by Elsevier B.V. All rights reserved.
Table 1
Amino acid alignments of the selected four peptides
Peptides Amino acid alignments Frequency (total 27)
GD3P1 LAPPRPRSELVFLSV 16/27
GD3P2 PHFDSLLYPCELLGC 7/27
GD3P3 GLAPPDYAERFFLLS 3/27
GD3P4 RHAYRSMAEWGFLYS 1/27
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Biopanning used here was performed as described elsewhere [15].
Brieﬂy, a phage library (6.2 · 1010 titers) was subtracted by incubation
with mouse immunoglobulin-conjugated protein A-Sepharose beads
and the non-bound phage clones were incubated with 4F6-beads. After
which, the bead-bound phage clones were ampliﬁed by infection to
host bacterial cells. Experiments following the described above re-
peated three times. After the third round of biopanning, 30 phage
clones were randomly picked up and ampliﬁed. The amino acid align-
ments inserted in pIII protein of the phage clones were determined by
DNA sequence analysis. The classiﬁed phage clones were subjected to
phage ELISA.
2.3. DNA sequence
Each single strand DNA from the ampliﬁed phage clones was ana-
lyzed by dideoxynucleotide chain termination. An oligonucleotide 5 0-
TAACACTGAGTTTCGTCACCAGTA was used as an anti-sense
primer.
Both heavy chains and light chains of Mab were ampliﬁed by RT-
PCR from total RNA obtained from hybridoma by a QIAGEN RNA-
Easy Kit. The ampliﬁed fragments were inserted into pT7 Blue3 blunt
vector (Novagen) and subjected to DNA sequence. T7 primer, U19
primer, and oligonucleotides shown in Figs. 3 and 4 were used for
the sequencing reaction.
2.4. Generation of hybridoma producing antibody against GD3
MAPs in a buﬀered solution of very small size protoliposomes
(VSSP) particles (kindly provided by Dr. Luis Fernandez [19], Center
of Molecular Immunology, Havana, Cuba) and Montanide ISO 51
were mixed to form an emulsion. Three CD-1 mice were immunized
by injection i.p. of emulsion containing 30 lg of MAPs. The schedule
of immunization was one injection every two weeks for two or six
months. The sera were assayed by ELISA for their capacity to bind
the peptides and GD3. The spleen cells of the mice whose sera reacted
the strongest with GD3 were fused with mouse myeloma SP2 cells
using polyethylene glycol. Hybridoma fusions were screened against
GD3. The positive clones were grown and expanded for mass produc-
tion. All cells used in the present experiments were cultured in RPMI
1640 medium containing 10% FBS.
2.5. ELISA
The phage clones, MAPs, and gangliosides were used as antigens in
ELISA. The individual phage clones (1010 titers/well), MAPs (100 ng/
well), and gangliosides (1 lg/well) were ﬁxed on 96 well micro titer
plates (Maxisorp, Nunc). After blocking the plates with blocking buﬀer
(PBS containing 1% BSA with or without 0.02% triton X-100), anti-
body-containing samples were added to each well. After 2 h incuba-
tion, each plate was washed and subjected to 1 h incubation with
second antibodies bearing HRP. Visualization was done with tetra-
methyl benzidine (TMB) microwell peroxidase substrate (KPL, Gai-
thersburg, MA). Absorbance was measured at 450 and 620 nm with
an ELISA reader.
2.6. FACS
Supernatants of the hybridoma cells were incubated with human
melanoma cell line, SK MEL-28 cells at 4 C for 30 min. After washing
the cells, FITC-labeled second antibodies were incubated at 4 C for
30 min. Fluorescence intensity of cell surface was analyzed by FACS.
FITC-labeled anti-mouse IgG3 or FITC-labeled anti-mouse IgG1 were
used as second antibodies and mouse IgG1 and mouse IgG3 were used
as negative controls.
2.7. Immunohistochemistry
Frozen, serial tissue sections (5 lm) of unﬁxed human melanoma
were collected on glass slides and ﬁxed with acetone at 20 C for
10 min. After which, the slides were blocked with 5% goat serum con-
taining PBS for 15 min. The slides were incubated with primary anti-
bodies for 45 min at room temperature. After washing with PBS, the
slide was incubated with biotinylated second antibodies (anti-mouse
IgG) for 15 min at room temperature, and then was incubated with
HRP-conjugated streptavidin. Each tissue section was stained with
DAKO immunoperoxidase kit. Hematoxylin was used as counter stain-
ing. A Mab (KM48) against keratinocyte was used as negative control.3. Results
3.1. Selection of GD3-replica peptides
Preparation of peptides that bind to anti-GD3 Mab, 4F6,
was performed using a phage library. Recovery of the phage
increased to 0.58% in third round, as compared with the recov-
ery rates in the ﬁrst round (0.0003%) and in the second round
(0.04%). Thirty randomly picked up clones from the third
round were subjected to DNA sequences and the deduced ami-
no acids are shown in Table 1. A total number of 27 peptides
were obtained and divided into 4 groups (GD3P1, GD3P2,
GD3P3, and GD3P4).
There were two consensus alignments as follows, Leu-Ala-
Pro-Pro-(X)8-Leu-Ser in GD3P1 and GD3P3, and Ala-(X)4-
Ala-Glu-(X)2-Phe-Leu-X-Ser in GD3P3 and GD3P4. Whereas
no conclusive consensus sequence was observed in GD3P2 and
the other three peptides, except for Glu-Leu-Z (Z: Val or Leu)
between GD3P2 and GD3P1.
3.2. Binding of the GD3-replica peptides to Mab 4F6
Binding between GD3-replica peptides and 4F6 is shown in
Fig. 1A. Binding of 4F6 to GD3P1, GD3P3, and GD3P4 was
observed, but not to GD3P2. Dose-dependent binding activi-
ties of phage to 4F6 were in the increasing order
GD3P4 > GD3P3 > GD3P1.
Binding activity of 4F6 to MAPs by ELISA is shown in
Fig. 1B. 4F6 bound to GD3P3 and GD3P4, however, the bind-
ing to GD3P1 was weaker compared with those to the phage
clones, GD3P3 and GD3P4 (Fig. 1A). The binding proﬁles
of 4F6 to the MAPs of GD3P3 and GD3P4 immobilized on
the plastic wells were dose-dependent and the binding of 4F6
to GD3P4 was slightly stronger than to GD3P3. On the other
hand, none of these peptides bound to a Mab (IgG3) recogniz-
ing both GD2 and GD3 (data not shown). Moreover, neither
an anti-GD3 Mab (IgM) nor an anti-O-acetyl GD3 Mab
(IgG3) bound to the peptides (data not shown). These results
suggested that the obtained peptides bound to 4F6 speciﬁcally
and closely mimic a part of GD3 structure.
3.3. Inhibition of GD3-replica peptides on the binding between
4F6 and GD3
Inhibitory eﬀect of GD3-replica peptides on the binding of
4F6 to GD3 was examined. 4F6 was incubated with GD3 or
GD3-replica peptides, which were immobilized on 96 well
plates in advance. After which, each supernatant was trans-
ferred into a GD3-coated 96 well plate then subjected to ELI-
SA to see the residual 4F6 (Fig. 1C). The 4F6 binding to the
GD3-coated plate decreased in a dose-dependent manner,
and the inhibition potencies found for GD3P3 and GD3P4
were similar to that of GD3.
When 4F6 and various concentrations of GD3 or GD3-rep-
lica peptides were added without pre-incubation into a GD3-
coated 96 well, the binding of 4F6 to GD3 was inhibited by
Fig. 1. Binding to 4F6 of the GD3-replica peptides. (A) Phage ELISA.
Each phage clones were ampliﬁed and concentrated. Various concen-
trations (1010/well to 1012/well) of phage clones were ﬁxed and
subjected to ELISA as described in Section 2. Wild type of phage
clone was used as control. The experiment was done in triplicate and
each column shows the average. (B) Dose dependency of the binding of
4F6 to GD3-replica peptides. Various concentrations of the individual
MAP was ﬁxed and subjected to binding of 4F6. (C) Inhibitory eﬀect
of GD3-replica peptides on the binding of 4F6 to GD3. Various
concentrations of GD3 or the MAP were ﬁxed on the 96 well plates
and incubated with 4F6 for 2 h in advance. Each supernatant
containing the non-absorbed 4F6 was transferred into GD3-coated
another plates and subjected to ELISA. The experiments were done in
triplicate and values and error bars show averages and S.D.s,
respectively.
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peptides were required to obtain a signiﬁcant level of inhibition
(data not shown).3.4. Anti-GD3 Mabs produced by GD3P4
In order to conﬁrm that the obtained peptides truly mimic a
part of GD3, whether the peptides can induce antibodies
against GD3 was investigated by immunizing mice with the
peptides. MAP for each peptide was used as antigen and the
antibody producing activity against GD3 was determined.
GD3P3 and GD3P4 were more eﬀective than GD3P1 and
GD3P2 in terms of antibody response in mice (data not shown).
In order to produce Mabs recognizing GD3 by immunizing
with peptides, MAP of GD3P4 was selected as the antigen. Fi-
nally, two Mabs (3D2 and 2C6) were obtained. The isotype of
3D2 was IgG1 with k light chain, 2C6 was an IgM, whereas 4F6
was an IgG3 with k light chain (data not shown).
Binding of the two Mabs was assessed by immunostaining
on thin-layer chromatography plate (ITLC) using a ganglio-
side fraction puriﬁed from human melanoma tumors
(Fig. 2A). Mabs 3D2 and 4F6 bound speciﬁcally to GD3
and not to any other tested ganglioside, whereas no ganglio-
side was recognized by Mab 2C6 using this technique. Binding
speciﬁcity of 3D2 was also investigated using bovine brain
ganglioside fraction (Fig. 2B). 3D2 slightly bound to GT1b
(arrow), suggesting that 3D2 recognizes NeuAca2-8NeuAca2-
3Gal structure. 4F6 reacted with only GD3.
3.5. FACS and immunohistochemistry
Experiments were carried out to determine whether the ob-
tained Mabs recognize GD3 on human melanoma cell surface
(Fig. 2C). Both Mabs 4F6 and 3D2 bound the human mela-
noma SK MEL-28 cells and approximately 82% of the cells
were recognized by 4F6, whereas 3D2 stained 13.7% of the
melanoma cells. The Mab 3D2 shows binding to the cell sur-
faces of the melanoma cell line but the binding activity is
rather weaker compared to that of 4F6.
Immunostaining of tumor tissue with 3D2 was performed
(Fig. 2D). The melanoma was strongly reactive with 4F6 and
less reactive with 3D2, whereas control staining with Mab
KM48 was negative. A clear-cut both peripheral and cytoplas-
mic staining of the tumor cells is observed with 4F6 antibody,
whereas the staining with 3D2 seems to be on the membranes
of tumor cells.
3.6. DNA sequence of heavy chain and light chain of 4F6 and
3D2
To clarify the relationship between these similarities at the
molecular level, DNA alignments of variable regions (heavy
chain variable region, VH; light chain variable region, VL) were
investigated (Figs. 3 and 4). Thereafter, the full length of the
heavy chain was ampliﬁed, using oligonucleotides from each
VH region as sense primers, and completed. From the full-
length sequences of two Mabs, it was conﬁrmed that the iso-
types of 4F6 and 3D2 were, respectively, IgG3 and IgG1.
By comparing the respective VH of Mabs 4F6 and 3D2, it
can be seen that only 18 point mutations were detectable at
the nucleotide level. Interestingly, only six amino acid substitu-
tions (3Kﬁ Q, 19KﬁM, 37Vﬁ I, 58Tﬁ I, 75Aﬁ S,
77Gﬁ S, and 81LﬁM) could be observed. When the com-
plementarity-determining regions (CDR) were compared,
there were one, two, and three point mutations in CDR1,
CDR2, and CDR3, respectively. Five of the six mutation sites
were silent and only one mutation resulted in amino acid sub-
stitution (58Tﬁ I) in CDR2. Furthermore, there were high
similarities in V–D–J segments between 4F6 and 3D2.
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Fig. 2. Production of anti-GD3 Mabs by immunization of GD3P4. (A) ITLC. Ganglioside fraction extracted from human melanoma cells were
developed on a high-performance thin-layer chromatography plate. All ganglioside bands were detected with resorcinol-HCl reagent and GD3 was
detected by the individual Mabs shown in the ﬁgure. (B) Binding speciﬁcity of 3D2. Bovine brain ganglioside fraction was used. (C) FACS analysis.
Human melanoma cell line, SK-MEL 28 cells were used for binding study of 3D2 and 4F6 for FACS analysis. (D) Immunohistochemistry with 4F6
and 3D2. Immunohistochemistry was carried out described in Section 2. Antibody-labelled tumors were colored in red. The blue coloration of nuclei
is due to hematoxylin as counterstaining. Pictures at 10· magniﬁcation allow the comparison between the antibody-labelled tumor cells and the
unstained portions of the melanoma tumor.
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mined (Fig. 4). By comparing the DNA and amino acid se-
quences, the mutation sites were two in CDR1 and one in
CDR3. Their deduced amino acid residues (30S, 35A, and
95T) in 4F6 were substituted to Thr, Val, and Ser in 3D2,
respectively. These individual substitutions occur among quite
similar amino acids indicating that the substitutions seem not
serious enough to alter the protein structure critical for the
antigen-binding property. The V–J segments in 3D2 were sim-
ilar to those in 4F6, except for cytidine to guanine at 284.4. Discussion
Since Jerne advocated the idiotype network hypothesis [20],
the fact that variable regions in some anti-Id antibodies in-
clude the internal images of the antigens has been documented
[21–23]. Many anti-Id antibodies are used in place of the origi-
nal antigens to induce antigen-speciﬁc immune responses.
However, administration of the whole anti-Id antibodies
in vivo often caused unexpected allergic responses. Therefore,an unwanted production of excessive amounts of irrelevant
antibodies should be considered. Replacing the internal images
with oligopeptides could represent an alternative approach.
Here we succeeded in obtaining GD3-replica peptides from a
phage peptide library using an anti-GD3Mab, 4F6. There were
some consensus sequences between GD3P3 and GD3P4 (Ala-
(X)4-Ala-Glu-(X)2-Phe-Leu-X-Ser). A carboxyl (–COOH)
group of Glu may mimic that of sialic acid, and phenyl group
of Phe and hydroxyl (–OH) group of Ser may mimic the bone
structure of the carbohydrates. Moreover, there were Trp and
Tyr in GD3P4. Amino group and indole group also seem to mi-
mic the partial structure of carbohydrates [16,19,24]. However,
any deduction about which corresponding amino acid is
accountable for which part of GD3 structure is impossible from
the present data.
The consensus sequence between GD3P3 and GD3P4 is
mainly present at the C-terminus side (Ala-Glu-X-X-Phe-
Leu-X-Ser). The nonamer peptide at C-terminus (GD3P4-
C9) was thought to be enough to bind to 4F6. However,
GD3P4-C9 neither bound to 4F6 nor inhibited the binding be-
tween 4F6 and GD3 (data not shown), indicating that the
Fig. 3. Comparison of sequence of heavy chains between 4F6 and 3D2. Both heavy chains were ampliﬁed by RT-PCR, inserted into a cloning vector,
and transformed into E. coli DH5a. Each 5 individual bacterial colonies were randomly picked up and subjected to DNA sequence. Oligonucleotides
used for sequence were underlined. Amino acid sequences were deduced from the DNA sequences. Both 5 clones had the same sequences. 4F6 and
3D2 were, respectively, conﬁrmed as IgG3 and IgG1. Possible positions corresponding to CDR1, CDR2, and CDR3 were shown as square. These
sequence data are available from GenBank under Accession No. AY498569.
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for binding to 4F6 to form the stereo structure of GD3.
Willers et al. reported the selection of four GD3-replica pep-
tides by using a phage peptide library and anti-GD3 Mab [25].
By comparing those sequences with the four peptides obtained
in the present study, no signiﬁcant common sequences were
seen, suggesting that the individual Mabs used in the respective
study may recognize diﬀerent parts of the GD3 structure.
The immunogenicity of carbohydrates is generally low and
the immune response is known to be T cell-independent. It will
be of major importance to determine whether the immuniza-
tion with carbohydrate-mimicking peptides (in terms of anti-
carbohydrate antibody binding peptides) can convert the
immune response from T-independent to T cell-dependent for
the production of carbohydrate recognizing antibodies. The
obtained Mab 3D2 was IgG1 whereas 4F6 was IgG3. The pres-
ent results may support the expectations described above,
even if further detailed studies are necessary to conﬁrm these
ﬁndings.
Although anti-carbohydrate antibodies induced in animals
by immunization with carbohydrate-mimicking peptides were
already described [26,27], the previous reports showed the pro-duction of polyclonal antibodies. The present study is the ﬁrst
to prove that Mabs can be successfully obtained through an
immune response to glyco-replica peptides.
We have also given evidence that the variable regions of the
obtained Mab produced by a peptide antigen (GD3P4) are
quite similar with those of the original Mab produced by the
carbohydrate antigen (GD3). Interestingly, V–(D)–J segments
in both heavy and light chains of two Mabs are almost identi-
cal, except for a few point mutations which may be located in
the position of joint between D–J or V–J segment. Both Mabs
have lambda light chain, nevertheless it is rare to produce
lambda light chain-containing antibodies in mice [28]. Taken
together, we can speculate that there may be present the dom-
inantly used gene for constructing antibodies when the anti-
gens are exposed on antigen-presenting cells (APCs) with
certain speciﬁc conformations depending of whether the anti-
gen is a peptide or a carbohydrate.
These results support a mechanism of initiation of some
autoimmune diseases that are caused after infectious diseases
[29–32]. For example, regarding the three-dimensional struc-
ture, we can say that the shape of a protein antigen or metab-
olized fragment antigen derived from microorganisms is
Fig. 4. Comparison of sequence of light chains between 4F6 and 3D2. Variable regions of both light chains were ampliﬁed by RT-PCR using
oligonucleotides as primers (underlined) and the DNA sequences were analyzed as same methods for heavy chains (Fig. 3). Oligonucleotides used as
primers underlined in the ﬁgure are for ampliﬁcation of lambda chain and no bands were ampliﬁed by many oligonucleotides for kappa chain.
Lambda chain was detected by Isotyping Kit in both Mabs (data not shown). Together with these results, both light chains consist from lambda
chain. Possible positions corresponding to CDR1, CDR2, and CDR3 were shown as square. These sequence data are available from GenBank under
Accession No. AY498568.
I. Popa et al. / FEBS Letters 580 (2006) 1398–1404 1403similar to the shape of a glycoconjugate of the host tissues and
the production of antibodies against this antigen(s) may lead
to the onset of an autoimmune disease.
Present report indicates that certain oligopeptides can ex-
pose the internal image of the variable region in anti-Id anti-
bodies. It remains to show how GD3P4 should be modiﬁed
to expose it on the APCs with keeping GD3-mimicking form
in order to produce anti-GD3 antibodies more eﬀectively.
When this question is answered, mimicking peptide vaccines
or peptide-coding DNA vaccines will be available for therapy.
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